Senhwa Biosciences, Inc
Biotechnology - , California, United States
Senhwa Biosciences, Inc Employees
Senhwa Biosciences, Inc Senior Management
Senhwa Biosciences, Inc Details
Senhwa Biosciences, Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer.Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan. Senhwa's CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwa's CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair protein XRCC1 and subsequently enhance the activity of DNA damaging chemotherapy agents. Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.
Senhwa Biosciences, Inc Technologies
Frameworks and Programming Languages
Ruby On Rails
Captcha
reCAPTCHA
Email Providers
Outlook
Load Balancers
Apache
Other
Microsoft Office 365
Hosting
DigitalOcean